Ascent Investment Holdings Sold 10.45% stake in Amber Enterprises; promoter offloads 5% in Max Healthcare

WF Asian Reconnaissance Fund and Smallcap World Fund bought 77 lakh and 2,37,77,803 shares, respectively, in Max Healthcare at Rs 110.70 per share

Ascent Investment Holdings sold 10.45 percent equity stake in Amber Enterprises, the market leader in room air conditioners via open market transactions on September 11.

It sold 9,86,646 equity shares in Amber at Rs 1,837.78 per share and 23,02,173 shares at Rs 1,835.14 per share, bulk deals data available on the National Stock Exchange (NSE) showed.

As a result, its shareholding in Amber has fallen to 10.47 percent now from 20.92 percent held on June 30.

Promoter Kartar Singh sold 275,000 equity shares in Amber (representing 0.87 percent of its total paid-up equity) at Rs 1,841.33 per share on the NSE. He held 2.25 percent stake in company as of June 30.

Vittoria Fund - OC and Oxbow Master Fund acquired 1,62,171 and 4,18,075 equity shares, respectively, in Amber at Rs 1,835.03 per share. Newport Asia Partners Fund and Newport Asia Institutional Fund bought 1,73,979 and 2,21,857 shares, respectively, at Rs 1,839.48 per share.

Among others deals, Yogeshkumar C Patel sold 2,28,964 shares in Jiya Eco-Products at Rs 8.89 per share and Gretex Share Broking sold 2 lakh shares in Suumaya Lifestyle at Rs 31 per share on the NSE.

On the BSE, promoter entities sold total 5.14 percent equity stake in Max Healthcare Institute via open market transactions on September 11.

Promoter Analjit Singh sold 58,18,021 shares in company (i.e. his entire shareholding representing 0.64 percent of its total paid-up equity) at Rs 110.70 per share. Max Ventures Investment Holdings too sold 4,07,50,158 shares at the same rate. It held 10,26,31,287 equity shares (or 11.35 percent of its total paid-up equity) as of June 30.

WF Asian Reconnaissance Fund and Smallcap World Fund bought 77 lakh and 2,37,77,803 shares, respectively, in Max Healthcare at Rs 110.70 per share.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

SD Solutions

Search This Blog